GREENVILLE, SC – Pharmaceutical Associates Inc (“PAI”), a leader in liquid unit-dose, bottle prescription, and over-the-counter medications, announced today the appointment of Paul Campanelli, former CEO of Endo Pharmaceuticals to its Board of Directors.
Read MoreWe are excited to announce the successful exit from our platform investment in West Dermatology through the sale of the business to Sun Capital Partners, Inc. Over the course of EHP's ownership, the company doubled the number of its clinics, acquired 22 practices and completed numerous organic expansion initiatives.
Read MoreNEW YORK, NY (Dec. 17, 2019) — Enhanced Healthcare Partners (“EHP”), a leading New York-based private equity firm focused on investing in middle-market healthcare businesses, today announced the appointment of Dave Prendergast as Vice President – Business Development, effective immediately.
Mr. Prendergast joins EHP to lead the firm’s business development efforts, where he will focus on identifying investment opportunities in founder and entrepreneur-led lower middle-market healthcare businesses in North America, targeting platforms between $50 and $250 million in enterprise value in the healthcare services sector including provider-based services, pharma services, payor services and technology-enabled services.
Read MoreBacking will propel PAI’s market leadership position and help capitalize on growth opportunities
We are excited to announce the platform acquisition of Pharmaceutical Associates, Inc. (“PAI”) completed in partnership with Bourne Partners Strategic Capital. A leader in liquid unit-dose, bottle prescription and over the counter medications, PAI manufactures and markets liquid pharmaceuticals and is at the forefront of innovative packaging solutions being one of the first manufacturers to develop vertically integrated unit-dose packaging.
Read MoreFund will further expand the firm’s commitment to investing in middle-market healthcare companies
We are pleased to announce the closing of our newest fund, Enhanced Healthcare Partners, L.P., which has raised $300 million of committed capital with access to $600 million in total equity to invest. The fund will invest in founder and entrepreneur-led lower middle-market healthcare businesses with a focus on the physician services, pharma services, payor services and healthcare technology sectors.
Specifically, the fund will target healthcare platforms with enterprise value in the $50 and $250 million range. This latest fund represents the third fund that EHP’s partners have led together.
Read MoreWindsor, Connecticut – January 3, 2019— SCA Pharma, an FDA approved 503B sterile-compounding organization, announced today that they have been awarded a group purchasing agreement for Outsourced I.V. Admixture Services with Premier Inc.
Beginning January 1, 2019, this new agreement allows Premier members, at their discretion, access to a wide range of outsourced pharmaceuticals. SCA features an extensive product catalog containing products in the following pharmaceutical categories:
Analgesics, Anesthetics, Antiarrhythmics, Antibiotics, Anticholinergics, Anticoagulants, Antihypertensive Drugs, Diuretics, Electrolytes, Neuromuscular Blockers, Opioid Analgesics, Oxytocic Agents, Reversal Agents and Vasopressors.
Read More